Sodium-glucose co-transporter 2 (SGLT2) inhibitors block glucose reabsorption in the renal
proximal tubule, an insulin-independent mechanism that plays a critical role in glycemic …

The specific sodium–glucose cotransporter 2 inhibitors (SGLT 2 inhibitors) inhibit glucose
reabsorption in proximal renal tubular cells, and both fasting and postprandial glucose …

Large placebo-controlled clinical trials have shown that sodium-glucose cotransporter-2
inhibitors (SGLT2i) delay the deterioration of renal function and reduce cardiovascular …

Type 2 diabetes mellitus (T2DM) is a growing public health concern worldwide. Numerous
drug classes are available for treatment, however, their efficacy with regard to diabetes …

The development of sodium-glucose transporter 2 inhibitor (SGLT2i) broadens the
therapeutic strategies in treating diabetes mellitus. By inhibiting sodium and glucose …

Abstract Type 2 diabetes (T2D) is one of the most common causes of chronic kidney disease
(CKD) and cardiovascular (CV) disease. Until recently, glycemic and BP control were the …

SGLT2 inhibitors are antihyperglycemic drugs that protect kidneys and the heart of patients
with or without type 2 diabetes and preserved or reduced kidney function from failing. The …

Sodium glucose cotransporter 2 inhibitors (SGLT2i) constitute a promising drug treatment for
heart failure patients with either preserved or reduced ejection fraction. Whereas SGLT2i …

Abstract Sodium/glucose cotransporter-2 inhibitors (SGLT2i) are a new type of glucose-
lowering drug that can reduce blood glucose by inhibiting its reabsorption in proximal …

Heart failure (HF) continues to be a serious public health challenge despite significant
advancements in therapeutics and is often complicated by multiple other comorbidities. Of …